Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
3 Healthcare Stocks Topping a 2025 List of Dividend Yields
08:27pm, Wednesday, 12'th Nov 2025
Bristol Myers Squibb has a high dividend yield, is very cheap, and may have better growth prospects than it might seem at first glance. Pfizer now has a 7% yield, and may have found a solution to its
Kahn Brothers' Strategic Moves: GSK PLC Sees a -3.08% Impact
12:00pm, Wednesday, 12'th Nov 2025
Exploring Kahn Brothers (Trades, Portfolio)' Recent 13F Filing and Investment Strategies Kahn Brothers (Trades, Portfolio) recently submitted their 13F filing
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, and Bristol Myers Squi
Allworth Financial LP Boosts Stock Position in Bristol Myers Squibb Company $BMY
03:41am, Wednesday, 12'th Nov 2025
Allworth Financial LP boosted its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 37.4% during the second quarter, according to the company in its most recent disclosure with the Sec
Final Trade: UNH, OIH, AMD, BMY
06:28pm, Tuesday, 11'th Nov 2025
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Jim Cramer Is Backing Off Bristol-Myers, But These 2 Chinese Stocks Are Good
08:08am, Tuesday, 11'th Nov 2025
On CNBC's “Mad Money Lightning Round,” Jim Cramer said he is backing off on Bristol-Myers Squibb Company (NYSE:BMY).
Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?
09:56am, Monday, 10'th Nov 2025
Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.
5 High-Yield Blue-Chip Dividend Giants Set to Soar If Rates Fall to 3%
07:42am, Thursday, 06'th Nov 2025
Investors love dividend stocks, especially the blue-chip variety, because they offer a significant passive income stream and have massive total return potential.
Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
02:47pm, Wednesday, 05'th Nov 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes.
Bristol Myers reaches $239 million settlement over psoriasis, MS drugs
11:36am, Wednesday, 05'th Nov 2025
Bristol Myers Squibb reached a $239 million settlement of claims that former Celgene shareholders were defrauded about prospects for the psoriasis drug Otezla, and multiple sclerosis treatment now kno
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
10:01am, Wednesday, 05'th Nov 2025
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors
09:00am, Tuesday, 04'th Nov 2025
PHILADELPHIA & SAN FRANCISCO--(BUSINESS WIRE)--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a cli
Bristol-Myers Squibb: Way Too Cheap At 7x P/E
08:00am, Tuesday, 04'th Nov 2025
Bristol-Myers Squibb is a compelling value and income opportunity, trading near 52-week lows with a 5.4% dividend yield and low forward P/E. BMY's growth portfolio, led by Opdivo, Reblozyl, and Breyan
Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth
06:06pm, Monday, 03'rd Nov 2025
Bristol-Myers Squibb (BMY) remains a "Strong Buy" rating, driven by robust growth in its hematology and cardiovascular portfolios, especially Breyanzi and Camzyos. Breyanzi and Reblozyl achieved impre
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership
10:29am, Monday, 03'rd Nov 2025
BioNTech SE (NASDAQ:BNTX) reported a third-quarter per-share loss of 14 cents (12 cents in euros) on Monday, a turnaround from earnings of 81 cents reported a year ago, missing the consensus earnings
